Skip to main content
. 2019 Oct 16;39(42):8217–8224. doi: 10.1523/JNEUROSCI.1159-19.2019

Figure 1.

Figure 1.

Suppressors of dysfunctional cellular pathways in ALS/FTD identify putative targets for therapeutic development. The etiology of ALS/FTD is complex, involving a number of independent cellular processes that lead to varied degenerative symptoms. Nevertheless, a single suppressor can reduce multiple symptoms, an encouraging outlook for therapeutic target identification by genetic modifier screens.